Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides
Status:
Unknown status
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
This study evaluates the effectiveness - as judged by complete response - of a single
four-day treatment with the fusion protein A-dmDT390-bisFv(UCHT1) compared to oral Zolinza
(Vorinostat), in a randomized 2-arm trial after a maximum of 12 months of treatment. Patient
eligibility is stage IB/IIB mycosis fungoides with mSWAT < 50 who have never had lymphoid
disease or a prior bone marrow / HSCT transplant.
Phase:
Phase 2
Details
Lead Sponsor:
Angimmune LLC
Collaborators:
City of Hope National Medical Center Columbia University Dana-Farber Cancer Institute Feinberg School of Medicine, Northwestern University H. Lee Moffitt Cancer Center and Research Institute Ohio State University Comprehensive Cancer Center Rush University Medical Center Scott and White Hospital & Clinic Stanford University Thomas Jefferson University University of Arkansas University of Colorado Denver School of Medicine Barbara Davis Center University of Texas Southwestern Medical Center University of Washington Vanderbilt University School of Medicine Washington University School of Medicine Yale University